Q4 2025 capped a year of expansion for GPI across international markets. The total value of new contracts signed reached €27 million, supported by the major agreement with the Welsh Blood Service.
Software
Software continued to be the main driver of international growth, with new contracts totalling €24.2 million, led by the strong performance of the Gpi4Med.BLOOD suite. Of particular interest is the entry of GPI’s blood management solutions into Senegal, through a nationwide agreement. The Group’s presence in the Middle East was further strengthened, with orders worth €4 million across Saudi Arabia, the United Arab Emirates and Jordan. These markets also delivered encouraging feedback on GPI’s cross-selling strategy: alongside the traditional transfusion medicine software offering, new agreements were signed for laboratory information systems and anatomical pathology solutions (LIS & Pathology).
The Hospital Information System (HIS) confirmed its competitiveness with new contracts worth €2.6 million in Germany and Austria, across both the public and private sectors.
Automation
Automation signed contracts worth €2.8 million, driven by Riedl, the robot for automated pharmaceutical logistics. Riedl continues to show strong geographic diversification, with deliveries in China, the DACH region, Japan and Hungary, alongside maintenance contracts in the Middle East.
A positive 2025 that confirms consolidation in established markets and marks expansion into new geographic areas.
Learn more:
